{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:55:31Z","timestamp":1770987331203,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,10]],"date-time":"2010-05-10T00:00:00Z","timestamp":1273449600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p>Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, Berwaerts J. A randomized, placebo\u2010 and active\u2010controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.\u2028Bipolar Disord 2010: 12: 230\u2013243. \u00a9 2010 The Authors.\u2028Journal compilation \u00a9 2010 John Wiley &amp; Sons A\/S.<\/jats:p><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> To evaluate the antimanic efficacy and safety of paliperidone extended\u2010release (ER) tablets in patients with bipolar I disorder.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> This study included a 3\u2010week, double\u2010blind, acute treatment phase (paliperidone ER versus placebo, with quetiapine as control), and a 9\u2010week, double\u2010blind, maintenance phase (paliperidone ER versus quetiapine). Patients [n\u2003=\u2003493; Young Mania Rating Scale (YMRS) score \u2265 20] were randomized (2:2:1) to flexibly dosed paliperidone ER (3\u201312\u2003mg\/day), quetiapine (400\u2013800\u2003mg\/day), or placebo for the acute treatment phase. During the maintenance phase, patients assigned to placebo were switched to paliperidone ER but not included in analysis of efficacy.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Paliperidone ER was superior to placebo at the 3\u2010week endpoint {primary outcome; least\u2010squares mean difference in change from baseline in YMRS scores [95% confidence interval (CI)]: \u22125.5 (\u22127.57; \u22123.35); p\u2003&lt;\u20030.001} and noninferior to quetiapine at the 12\u2010week endpoint [least\u2010squares mean difference (95% CI): 1.7 (\u22120.47; 3.96)]. The median mode dose during the 12\u2010week treatment period was 9\u2003mg for paliperidone ER and 600\u2003mg for quetiapine. The most common (\u2265 10%) treatment\u2010emergent adverse events during the 12\u2010week period were: headache (16%), somnolence (10%), and akathisia (10%) for paliperidone ER; somnolence (21%), sedation and dry mouth (17% each), headache (14%), and dizziness (13%) for quetiapine. Body weight increase \u2265 7% from baseline to 12\u2010week endpoint was 8% with paliperidone ER and 17% with quetiapine. A higher percentage of paliperidone ER (13.9%) versus quetiapine patients (7.5%) \u2018switched to depression\u2019 at the12\u2010week endpoint.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Paliperidone ER (3\u201312\u2003mg\/day) was efficacious and tolerable in the treatment of acute mania.<\/jats:p>","DOI":"10.1111\/j.1399-5618.2010.00815.x","type":"journal-article","created":{"date-parts":[[2010,5,10]],"date-time":"2010-05-10T16:17:44Z","timestamp":1273508264000},"page":"230-243","source":"Crossref","is-referenced-by-count":87,"title":["A randomized, placebo\u2010 and active\u2010controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder"],"prefix":"10.1111","volume":"12","author":[{"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac F","family":"Nuamah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W","family":"Hough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Berwaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,10]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"42","article-title":"Global mental health","volume":"54","author":"Kastrup MC","year":"2007","journal-title":"Dan Med Bull"},{"issue":"6","key":"e_1_2_6_3_2","first-page":"4","article-title":"Toward an understanding of bipolar disorder and its origin","volume":"64","author":"Rush AJ","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000151520"},{"key":"e_1_2_6_5_2","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"American Psychiatric Association","year":"2002","journal-title":"Am J Psychiatry"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00212.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2007.58.6.855"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-6-27"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132613"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.4.1067342"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.2.193"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.09.012"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.01.017"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.03.003"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31802dda4a"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328314e1f3"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_6_19_2","unstructured":"Seroquel Prescribing Information.http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM191896.pdf. Last accessed April 6 2010."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_6_22_2","unstructured":"Johnson & Johnson Pharmaceutical Research.A study to evaluate the efficacy and safety of flexible doses of extended\u2010release (ER) paliperidone compared with flexible doses of quetiapine and placebo in patients with bipolar I disorder.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00309699?term=paliperidone+ER+bipolar&rank=3. Last accessed April 1 2010."},{"key":"e_1_2_6_23_2","first-page":"534","volume-title":"AIMS. Abnormal Involuntary Movement Scale. ECDEU Assessment for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.47.2.343"},{"key":"e_1_2_6_28_2","volume-title":"Multiple Comparisons and Multiple Tests Using SAS","author":"Westfall PTR","year":"1999"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2008.00611.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000082021"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00311-X"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0116"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.02.006"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-7-40"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00445.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.049965"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.05.014"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01204.x"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-5618.2010.00815.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-5618.2010.00815.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:25:34Z","timestamp":1698791134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-5618.2010.00815.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1399-5618.2010.00815.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-5618.2010.00815.x","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}